References
Shahdad SA, Taylor C, Barclay SC, Steen IN, Preshaw PM (2005) A double-blind, crossover study of Biotene Oralbalance and BioXtra systems as salivary substitutes in patients with post-radiotherapy xerostomia. Eur J Cancer Care (Engl) 14:319–326. doi:10.1111/j.1365-2354.2005.00587.x
Sugiura Y, Soga Y, Tanimoto I, Kokeguchi S, Nishide S, Kono K, Takahashi K, Fujii N, Ishimaru F, Tanimoto M, Yamabe K, Tsutani S, Nishimura F, Takashiba S (2008) Antimicrobial effects of the saliva substitute, Oralbalance, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. Support Care Cancer 16:421–424. doi:10.1007/s00520-007-0391-z
Sugiura Y, Soga Y, Yamabe K, Tsutani S, Tanimoto I, Maeda H, Kokeguchi S, Fujii N, Ishimaru F, Tanimoto M, Nishimura F, Takashiba S (2010) Total bacterial counts on oral mucosa after using a commercial saliva substitute in patients undergoing hematopoietic cell transplantation. Support Care Cancer 18:395–398. doi:10.1007/s00520-009-0789-x
Warde P, Kroll B, O’Sullivan B, Aslanidis J, Tew-George E, Waldron J, Maxymiw W, Liu FF, Payne D, Cummings B (2000) A phase II study of Biotene in the treatment of postradiation xerostomia in patients with head and neck cancer. Support Care Cancer 8:203–208
Conflict of interest
The authors have no conflicts of interest related to this letter.
Author information
Authors and Affiliations
Corresponding author
Additional information
All authors were affiliated with Okayama University, Okayama, Japan when the studies were performed.
Rights and permissions
About this article
Cite this article
Sugiura, Y., Soga, Y., Tanimoto, I. et al. With regard to our manuscripts on the commercial saliva substitute, Oralbalance®—its formula has been changed. Support Care Cancer 22, 3121–3122 (2014). https://doi.org/10.1007/s00520-014-2432-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-014-2432-8